Lexeo Therapeutics, Inc. Common Stock (NASDAQ: LXEO) is a Healthcare company (Biotechnology) with a market capitalization of $234M. The Maz Rating grades it against the other companies in its sector.
Lexeo Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.85, Lexeo Therapeutics, Inc. Common Stock trades at 1.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -45.3%, return on invested capital of -51.1% and a free cash flow yield of -37.3%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 8.69. Over the past 52 weeks the share price ranged from $2.55 to $10.99, with a beta of 1.64.
Lexeo Therapeutics, Inc. Common Stock does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Lexeo Therapeutics, Inc. Common Stock (LXEO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 70.1% / 30% · Interest income / Revenue 212000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 61.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 212000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 61.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 212000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.46% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 64.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 212000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 79.9% / 33.33% · (Cash+Recv) / Total Assets 79.9% / 33.33% · Interest income / Revenue 212000000.0% / 5% | Fail |
No. As of September 2026, Lexeo Therapeutics, Inc. Common Stock (LXEO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Lexeo Therapeutics, Inc. Common Stock is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 212000000.0% of each dividend: Lexeo Therapeutics, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.